Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients
This study has been completed.
First Received: September 2, 2008   No Changes Posted
Sponsored by: Gachon University Gil Medical Center
Information provided by: Gachon University Gil Medical Center
ClinicalTrials.gov Identifier: NCT00745407
  Purpose

Fenofibrate increases adiponectin levels, but reduces leptin levels


Condition Intervention Phase
Hypertriglyceridemia
Drug: fenofibrate
Phase IV

Study Type: Interventional
Study Design: Treatment, Crossover Assignment

Resource links provided by NLM:


Further study details as provided by Gachon University Gil Medical Center:

Study Start Date: January 2005
Study Completion Date: August 2008
Arms Assigned Interventions
fenofibrate 160 mg, placebo: Experimental Drug: fenofibrate

  Eligibility

Ages Eligible for Study:   25 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hypertriglyceridemia

Exclusion Criteria:

  • chronic liver disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00745407

Locations
Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405760
Sponsors and Collaborators
Gachon University Gil Medical Center
  More Information

No publications provided

Study ID Numbers: GMC 200511
Study First Received: September 2, 2008
Last Updated: September 2, 2008
ClinicalTrials.gov Identifier: NCT00745407     History of Changes
Health Authority: South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:
adipocytokines
insulin sensitivity
hypertriglyceridemic patients

Study placed in the following topic categories:
Antimetabolites
Metabolic Diseases
Hyperlipidemias
Hypertriglyceridemia
Antilipemic Agents
Procetofen
Metabolic Disorder
Insulin
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Antimetabolites
Metabolic Diseases
Hyperlipidemias
Hypertriglyceridemia
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antilipemic Agents
Procetofen
Pharmacologic Actions
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on September 10, 2009